Exousia Bio, Inc.
LMMY· OTC
Filed Oct 11, 2023 · 10-Q · 41 days after period end · 0001683168-23-007051
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Net Income | -$12.16K | -$12.97K |
| EPS Diluted | $0.00 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Exousia Bio, Inc. · CIK 1939937 · Engraved from SEC EDGAR
ended Aug 31, 2023 · filed Oct 11, 2023 · 41 d after period end